Jacob Brubaker, MD
Glaucoma Specialist · Sacramento, CANPI 1740433945
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AbbVie at 26.6% of the total. Reporting peaked in 2019 at $54,677 and has fallen 69.0% since, to $16,930 in 2025. Among glaucoma specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $454.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$61K
- Aerie Pharmaceuticals, Inc.$49K
- Alcon$38K
- NEW World Medical,inc.$26K
- Glaukos Corporation$21K
- Alcon Research LLC$15K
- plus $20K from 20 others
Across 388 payments — averaging $1598.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$263K
- Glaukos Corporation$204K
- Alcon Research LLC$88K
- Ivantis, Inc$50K
- Rxsight Inc$16K
What the payments were for
- Consulting fees$90,72540%
- Speaking & faculty fees$111,12748%
- Travel & lodging$9,7254%
- Food & beverage$16,6157%
- Education$1,0000%
- Gifts$2660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 189 | $60,960 |
| Aerie Pharmaceuticals, Inc. | 49 | $48,899 |
| Alcon | 94 | $38,145 |
| NEW World Medical,inc. | 43 | $25,846 |
| Glaukos Corporation | 39 | $20,650 |
| Alcon Research LLC | 5 | $14,523 |
| Iridex Corporation | 7 | $13,667 |
| Rxsight Inc | 12 | $4,354 |
| Ivantis, Inc | 9 | $1,056 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $356 |
| Novartis | 6 | $213 |
| Thea Pharma Inc. | 7 | $138 |
| Rayner Intraocular Lenses Limited | 5 | $108 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $59 |
| Nova Eye, Inc. | 1 | $54 |
| Tarsus Pharmaceuticals, Inc. | 3 | $51 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| Sun Pharmaceutical Industries Inc. | 3 | $49 |
| Biotissue Holdings Inc. | 3 | $49 |
| Sight Sciences, Inc. | 2 | $41 |
| Dompe US, Inc. | 1 | $36 |
| Omeros Corporation | 2 | $36 |
| Oyster Point Pharma, Inc. | 2 | $35 |
| Bausch & Lomb Americas Inc. | 2 | $33 |
| Carl Zeiss Meditec USA, Inc. | 1 | $27 |
| Harrow Eye, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$54,353
- Rocklatan$54,353
- XEN$26,013
- Hydrus Microstent$19,295
- Ahmed Glaucoma Valve$19,011
- Kahook Dual Blade$19,011
- DURYSTA$15,475
- iDose$8,017
- Clearpath$6,184
- Streamline$6,184
- Streamline Surgical System$5,808
- Voyager DSLT$5,000
- Via360$4,882
- iStent inject W$4,500
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$4,121
- LUMIGAN$3,561
- COMBIGAN$3,436
- XEN GLAUCOMA TREATMENT SYSTEM$2,613
- iStent Trabecular Micro-Bypass Stent System$2,000
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,300
How this compares
$229,457 in reported general payments places this provider in the 95th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 443 | $234,175 |
| RocklatanNetarsudil Mesylat/Latanoprost | 180 | $105,498 |
| RhopressaNetarsudil Mesylate | 178 | $88,390 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 265 | $65,529 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 206 | $44,479 |
| VyzultaLatanoprostene Bunod | 86 | $39,533 |
| CombiganBrimonidine Tartrate/Timolol | 99 | $38,775 |
| Alphagan PBrimonidine Tartrate | 72 | $28,423 |
| Latanoprost | 1,865 | $28,029 |
| Brimonidine Tartrate | 351 | $27,284 |
| Travoprost | 141 | $26,980 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,255 | $22,693 |
| Prednisolone Acetate | 337 | $16,396 |
| IyuzehLatanoprost/Pf | 34 | $15,211 |
| Timolol MaleateTimolol Maleate/Pf | 28 | $14,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis Multidose | $60,960 | $308,412625 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $48,899 | $193,888358 claims |
| AlconSimbrinza, Azopt | $38,145 | $73,801276 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $33 | $39,53386 claims |
| Thea Pharma Inc.Iyuzeh | $138 | $15,21134 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $356 | $13,558103 claims |
| NovartisTravatan Z | $213 | $9,12822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Sacramento
- Sina VahediSacramento$2K
- Tessnim AhmadSacramento$1K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.